Nutriop

Nesta and UKRI offer £6m for healthy aging start-ups

Latest articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...

VitaDAO announces “Longevity Molecule” research project

VitaDAO will use advanced machine learning to crunch the data from 1.04 billion prescriptions to understand the impact of drugs on human lifespan. VitaDAO, which...

Most read

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...
Supplement report

Editor's picks

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Sticking with glutathione could be a smart longevity choice

The body's "master antioxidant" glutathione is a powerful weapon in the fight for longevity, but it diminishes with age; AgelessRx has a range of...

Rise of the retrons – a new gene editing technique

Move over CRISPR... a new gene editing technique enables millions of genetic experiments to be performed simultaneously. Like the best B Movie ever, The Day...
Nutriop

New partnership provides £6m in investment and grants to progress improved health in later life.

Nesta – the UK’s innovation foundation for social good – and UK Research and Investment (UKRI) have announced a new two-year partnership to provide up to £6 million in combined investment and grant funding for healthy aging start-ups working to improve health outcomes in later life.

Longevity.Techology: This funding partnership is a significant step towards increasing healthy life expectancy in the UK, which has slowed dramatically as health inequalities have widened. Research shows that on average the poorest in society die around nine years before their more affluent peers, and experience ill health almost two decades earlier [1].

The new Nesta and UKRI fund aims to support companies between Seed stage to Series A offering products or services to increase healthy life expectancy and reduce health inequalities. Nesta is particularly looking to invest in start-ups that are focused on reducing loneliness – for instance for those transitioning to living in care – or supporting people to remain in work in later life, which is crucial to quality of life.

Potential investees can apply for between £250k and £1M of investment capital from Nesta Impact Investments. Nesta is making up to £3 million of funding available. Qualifying companies will then be eligible to apply for further match grant funding from UKRI.

Manish Miglani, Investment Director, Nesta Impact Investments, said: “Nesta is committed to increasing the average number of healthy years lived in the UK, whilst narrowing health inequalities. This £6 million partnership with UKRI will enable us to invest in innovative approaches, and solutions that can overcome an issue that is central to Nesta’s mission through Impact Investments. We are particularly interested in companies between Seed stage and Series A that are reskilling older people to reduce later years unemployment – further perpetuated by the ongoing pandemic – as well as solutions that can keep people healthy and independent for longer.”

George MacGinnis, Healthy Ageing Challenge Director, UK Research and Innovation said: “UKRI’s new partnership with Nesta will deliver meaningful investment in helping people live longer, high-quality lives with dignity. The Healthy Ageing Challenge sits at the heart of healthy ageing research and development in the UK and is an engine driving economic and social development. The issue of inequality in health and the effect it has on later years has yet to be solved.

“We can’t expect that just providing more of the same old products and services will address this. As a nation we need to encourage, support and nurture radical, disruptive approaches that change the game for people at risk of poor health outcomes, investing in prevention and supporting life choices that enable us to get ahead of the curve of health inequality later in life.”

The new £3m fund from Nesta is open for applications now, through to 31 March 2023. Nesta Impact Investment will invest between £250k and £1 million in successful applicant businesses. Successful applicants will then be able to apply for match funding from UKRI up to the same value as Nesta’s investment.

Visit Nesta Impact Investments for more details, eligibility criteria and to apply.

[1] https://bit.ly/3u5iHVI

Image credit: fauxelsPexels

Comment on this article

Eleanor Garth
Deputy Editor Now a science and medicine journalist, Eleanor worked as a consultant for university spin-out companies and provided research support at Imperial College London and various London hospitals in a former life.
Nutriop

Most popular

New NAD+ boosting longevity supplement hits the market

Elevant Prime dietary supplement contains a “high purity” form of NMN that has completed safety and toxicology testing. New York based health and wellness brand...

David Sinclair to co-chair $200 million biotech SPAC

Christian Angermayer's Frontier Acquisition Corp. holds significant longevity interest with David Sinclair and Peter Attia as Co-Chairs of the Board. Frontier Acquisition Corporation, a special...

JUVICELL sets sights on lifespan and healthspan

Ten ingredients, one capsule. JUVICELL is on a mission to deliver an all-in-one longevity supplement. Far from just supplementing their diet to ensure an adequate...

Spermidine: the mind-enhancing supplement

Scientists are finding that a high intake of dietary spermidine could slow down (or reverse) the brain aging process. Memory loss and slower brain function...
Supplement report

Related articles

Dyno Therapeutics closes $100m to accelerate gene therapy

Dyno Therapeutics closes $100 million Series A led by Andreessen Horowitz to accelerate AI-powered gene therapy platform. Dyno Therapeutics, Inc, a biotech applying AI to...

Huma’s $130m raise will scale its digital health platform

With the goal of bringing proactive, predictive care to all, Huma has $130 million financing from leading health and technology companies. The investment arms of...

Pacific AM hires healthcare manager Dani Saurymper for new fund

Pacific Asset Management has hired Dani Saurymper from AXA IM – new fund lined up for the healthcare manager. Pacific Asset Management (PAM) has announced...

Michael Greve commits €300m for rejuvenation start-ups

The founder of Forever Healthy has committed €300 million to advance rejuvenation biotech start-ups – plus exclusive insights from Michael Greve. Michael Greve, founder of...

Capsida Biotherapeutics emerges from stealth with $140m

Versant Ventures and Westlake Village BioPartners launch next-generation gene therapy company with $50m series A; AbbVie collaboration provides $90m for gene therapies for CNS...
Supps report ad middle